BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double‐Blind Randomised Interventional Phase 2b Trial
BIO101 bei sarkopenen älteren Menschen mit Risiko für Mobilitätsbehinderung: Ergebnisse einer doppelblinden randomisierten Interventionsstudie der Phase 2b
Journal of Cachexia, Sarcopenia and Muscle · 2025-04 · 16 (2)
DOI: 10.1002/jcsm.13750 ↗Auf einen Blick
Bei 233 sarkopenen älteren Menschen wurde BIO101 mit Placebo verglichen. Die 350-mg-Dosis zeigte im 400-m-Gehtest einen Vorteil, die Sicherheit war gut.
Fragestellung
Verbessert BIO101 bei gemeinschaftlich lebenden älteren Menschen mit Sarkopenie Muskel- und körperliche Leistungsfähigkeit und ist es sicher?
Methode
Randomisierte dreiarmige Interventionsstudie mit doppelblinder Behandlung; BIO101 175 mg bid, 350 mg bid oder Placebo; geplante Behandlung 6 Monate, bei 50 Personen bis 9 Monate.
Ergebnisse
233 randomisiert; 232 in FAS, 156 in PP. BIO101 350 mg bid verbesserte die Gehgeschwindigkeit im 400MWT um 0,07 m/s vs. Placebo in FAS (nicht signifikant) und um 0,09 m/s in PP (p = 0,008).
Einschränkungen
55 % der on-site End-of-treatment-Effizienzbewertungen gingen durch die COVID-19-Pandemie verloren; dadurch geringere Power.
Schlussfolgerung der Autor:innen
Nach 6 bis 9 Monaten zeigte BIO101 350 mg bid starke Trends für einen klinisch relevanten Effekt auf die Gehgeschwindigkeit im 400MWT nahe der MCID von 0,1 m/s. Die Sicherheit war gut.
Kernaussagen
- BIO101 350 mg bid verbesserte die Gehgeschwindigkeit im 400MWT
- Effekt in FAS nicht signifikant, in PP signifikant
- Sicherheitsprofil in beiden Dosierungen gut
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 03.03.2025. Verfasst von Roger A Fielding und 28 weiteren Autor:innen. Beteiligte Einrichtung: Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Mass…. Hauptthemen laut MEDLINE: Sarcopenia, Mobility Limitation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Mobilisation
Abstract (Originalsprache)
Background
Sarcopenia is a progressive muscle disorder that may lead to mobility disability. No pharmaceutical interventions are currently available, and treatment relies on physical exercise and nutrition. The aim of SARA‐INT was to investigate whether BIO101 (20‐hydroxyecdysone), an activator of the MAS receptor, is safe and improves muscle function and physical performance of community dwelling older sarcopenic patients.
Methods
SARA‐INT was a randomised three‐arm interventional study (BIO101 175 mg bid /350 mg bid/placebo) with a planned 6‐month treatment (up to 9 months in 50 subjects). Eligibility criteria for sarcopenia were meeting FNIH criteria for sarcopenia and Short Physical Performance Battery (SPPB) score ≤ 8/12 in men and women aged ≥ 65 years. Primary endpoint was the change from baseline (CFB) in gait speed (GS) measured by 400‐m walking test (400MWT), secondary endpoints being CFB in other physical performance tests.
Results
A total of 233 participants were randomised (mean age 75.5 ± 7.12; 54.3% female), of whom 232 and 156 were included in the full analysis set (FAS) and per‐protocol (PP) populations, respectively. Due to COVID‐19 pandemic, 55% of on‐site end‐of‐treatment efficacy assessments were lost, reducing the studies' power. In the primary analysis (mix of 6/9 months), BIO101 350 mg bid treatment after 6/9 months was associated with an improvement in the 400MWT of 0.07 m/s versus placebo in the FAS population (not significant) and of 0.09 m/s in the PP population ( p = 0.008). BIO101 350 mg bid treatment effect on the 400MWT GS was also observed in pre‐defined subpopulations at higher risk of mobility disability (0.0474 m/s for slow walkers, 0.0521 m/s for obese and 0.0662 m/s for chair stand sub‐score ≤ 2 from SPPB in the FAS population), with a trend for a dose response. BIO101 showed a good safety profile at both doses (number of subjects with related treatment emergent adverse events (TEAEs) of 13 (16.0%), 10 (13.3%) and 10 (13.5%) in the placebo, 175 mg and 350 mg BIO101 groups, respectively).
Conclusions
After 6 to 9 months of treatment, BIO101 350 mg bid showed strong trends consistent with a clinically relevant effect on the 400MWT GS, close to the minimal clinically important difference (MCID) in sarcopenia (0.1 m/s). This was also shown in predefined subpopulations at higher risk of mobility disability. BIO101 showed a good safety profile. Taken together, efficacy and safety data of this Phase 2 trial encourage us to pursue further development of BIO101 for the treatment of sarcopenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, USA.
- AMD Medical Group and National Institute of Clinical Research Inc., Garden Grove, California, USA.
- PMG Research of Wilmington, Wilmington, North Carolina, USA.
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.
- METHODS Core, Centre de Recherche Epidémiologie et Statistique Paris Sorbonne Cité (CRESS), Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1153, Paris, France.
- SAM CLINICAL RESEARCH CENTER/Science Advancing Medicine, San Antonio, Texas, USA.
ORCID-Profile: Cendrine Tourette, Waly Dioh, Rob van Maanen
Zitieren
APA
Fielding, R. A., Dao, M. M., Cannon, K., Desvarieux, M., Miller, S. S., Gimness, M. P., Brandon, D. M., Villareal, D. T., Bruyere, O., Bautmans, I., Rickner, K., Perry, R., Kritchevsky, S. B., Musi, N., Chehade, J. M., Kirstein, J. L., Gielen, E., Pickrell, P., Dilda, P., …, & Veillet, S. (2025). BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double‐Blind Randomised Interventional Phase 2b Trial. Journal of Cachexia, Sarcopenia and Muscle, 16(2). https://doi.org/10.1002/jcsm.13750
Vancouver
Fielding RA, Dao MM, Cannon K, Desvarieux M, Miller SS, Gimness MP, et al. BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double‐Blind Randomised Interventional Phase 2b Trial. Journal of Cachexia, Sarcopenia and Muscle. 2025;16(2). doi:10.1002/jcsm.13750
BibTeX
@article{Fielding2025,
author = {Fielding, Roger A and Dao, Michael M and Cannon, Kevin and Desvarieux, Moise and Miller, Sam S and Gimness, Michael Paul and Brandon, Donald M and Villareal, Dennis T and Bruyere, Olivier and Bautmans, Ivan and Rickner, Kyle and Perry, Robert and Kritchevsky, Stephen B and Musi, Nicolas and Chehade, Joe M and Kirstein, Judith L and Gielen, Evelien and Pickrell, Paul and Dilda, Pierre and Lafont, Rene and Margalef, Carole and Rolland, Yves and Del Signore, Susanna and Mariani, Jean and Agus, Samuel and Tourette, Cendrine and Dioh, Waly and van Maanen, Rob and Veillet, Stanislas},
title = {BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double‐Blind Randomised Interventional Phase 2b Trial},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2025},
volume = {16},
number = {2},
doi = {10.1002/jcsm.13750}
}
EUVIMED